Walleye Capital
HAE icon

Walleye Capital’s Haemonetics HAE Stock Holding History

Walleye Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,600
Closed -$128K – 4638
2025
Q4 		$128K Buy
+1,600
New +$108K ﹤0.01% 3760
2025
Q2 		– Sell
-8,300
Closed -$527K – 4700
2025
Q1 		$527K Sell
8,300
-5,900
-42% -$401K ﹤0.01% 2511
2024
Q4 		$1.11M Buy
14,200
+600
+4% +$48.2K ﹤0.01% 2291
2024
Q3 		$1.09M Buy
13,600
+13,200
+3,300% +$1.07M ﹤0.01% 2568
2024
Q2 		$33.1K Buy
+400
New +$35.2K ﹤0.01% 5031
2019
Q2 		– Sell
-2,000
Closed -$175K – 1852
2019
Q1 		$175K Buy
+2,000
New +$182K 0.03% 822

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's HAE Position: Q2 2026 in Review

Walleye Capital sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 66,359 shares — an estimated $3.74M sold.

Walleye Capital first reported a position in HAE in Q1 2019 and held it in 13 quarters. The position peaked at $14.7M in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Walleye Capital reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 66,359 Haemonetics shares in Q2 2026, an estimated $3.74M.
  • Walleye Capital first reported a position in Haemonetics in Q1 2019 and held it in 13 quarters.
  • Walleye Capital's Haemonetics position peaked at $14.7M in Q2 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.